IgM-Rheumatoid factor confers primary resistance to anti-PD-1 immunotherapies in NSCLC patients by reducing CD137+T-cells
Alessio Ugolini(The Wistar Institute), Marianna Nuti(National Institutes of Health), Tania Colasanti(Sapienza University of Rome), Fabrizio Conti(Policlinico Umberto I), Ilaria Grazia Zizzari(Sapienza University of Rome), Andrea Botticelli(Policlinico Umberto I), Hassan Rahimi(Sapienza University of Rome), Guido Valesini(Center for Rheumatology), Lidia Strigari(Azienda USL di Bologna), Fulvia Ceccarelli(Sapienza University of Rome), Aurelia Rughetti(Sapienza University of Rome), Paolo Marchetti(Istituto Dermopatico dell'Immacolata)
Cited by 17
Related Papers
A spectrum of monoclonal antibodies reactive with human mammary tumor cells.
|Proceedings of the National Academy of Sciences|1981|563
A monoclonal antibody (B72.3) defines patterns of distribution of a novel tumor‐associated antigen in human mammary carcinoma cell populations
|International Journal of Cancer|1982|327
Glucose-driven histone lactylation promotes the immunosuppressive activity of monocyte-derived macrophages in glioblastoma
|Immunity|2024|252
Polymorphonuclear myeloid-derived suppressor cells limit antigen cross-presentation by dendritic cells in cancer
|JCI Insight|2020|144
Myeloid Cells in Glioblastoma Microenvironment
|Cells|2020|144